InspireMD (NSPR)
(Real Time Quote from BATS)
$2.00 USD
0.00 (0.00%)
Updated Apr 29, 2024 12:36 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NSPR 2.00 0.00(0.00%)
Will NSPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NSPR
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
NSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for NSPR
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
InspireMD Boosts Executive Severance Benefits Ahead of Potential Takeover
InspireMD to Present Key Trial Results at LINC 2024
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
InspireMD announces abstract one-year follow-up results from C-GUARDIANS trial